Ikonisys Group enters Central America Market
through a Partnership and Distribution Agreement with Green Med Panama


Paris, November 18, 2024 - 7:30 a.m. CET - Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through a unique fully automated solution
for medical analysis laboratories, today announces the signing of a distribution agreement with Green
Med, a major distributor of medical devices in Panama and Central America. This collaboration is part
of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to
the region, based on four core initiatives.

The first step of the plan focuses on certification and importation of Ikonisys Group’s products into
Panama, leveraging the region’s logistical and operational advantages. Panama’s strategic position as
a logistics hub will enable streamlined distribution and access to Ikonisys Group's products across
Central America (including Costa Rica, Nicaragua, Honduras, Salvador, Guatemala and Belize).

The second pillar of this initiative involves introducing Liquid-Based Cytology (LBC) technology into
Panamanian healthcare facilities, which currently rely solely on traditional cytology methods. Through
this agreement, Ikonisys Group aims to modernize diagnostic processes, providing LBC solutions that
enhance diagnostic accuracy, improve sample quality, and optimize laboratory workflows.

Furthermore, Ikonisys Group will promote its FISH (Fluorescence In Situ Hybridization) technology to
major oncology diagnostic centers nationwide, offering high sensitivity testing for various oncological
applications and facilitating early and accurate cancer detection, ultimately improving patient
outcomes.

Finally, Ikonisys Group will establish a Temporary Association of Companies (ATI) with local partners
to collaborate with the Panamanian government on a bladder cancer mass screening project. This
program aims to provide early detection and preventive care for urinary tract diseases, a significant
public health concern in the region. Once the trial is validated, this screening program could be applied
across the region.

The initial market test will be conducted in Panama, chosen for its strategic location and advanced
healthcare infrastructure and will encompass the full product line of Ikonisys Group, serving as a
benchmark for subsequent launches across Central America.

“We are thrilled to partner with Green Med and all our participating operators,” stated Alessandro
Nosei, General Manager of Hospitex - Ikonisys Group. “The initial market test in Panama is a crucial
step towards global implementation of our strategy.”

Through this initiative, Ikonisys Group reaffirms its commitment to supporting cancer diagnostic
advancements in Panama and bringing cutting-edge diagnostic technology to Latin America, working
closely with local institutions to address pressing healthcare needs.



1/2
About Green Med
Green Med is a distributor accredited by the Ministry of Health in Panama, specific in the distribution of laboratory solutions
with a particular expertise in Cytology and Laboratory FISH. Company established in 2010 by Dr. Guglielmo Cupeiro Vargas,
founder of Panama Scrub Company SA.

About Hospitex
Hospitex is the world leading company for cytology standardized monolayer preparations. With CYTOfast it re-invented
cytological diagnostics. Hospitex offers a full range of integrated solutions aimed at streamlining diagnostic processes in
cytology. The global shortage of expertise in pathology requires tools and technologies that enable diagnostic safety,
efficiency and capacity building. In this area, Hospitex is recognized as the precision diagnostics player in cytology.

For more information: https://www.hospitex.com/en/


Contact
Hospitex
Marco Testini
Investor Relations
marco.testini@hospitex.com


About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable
detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic
applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy
platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor
Cells (CTC).

For further information, please go to www.Ikonisys.com



Contacts
Ikonisys NewCap NewCap
Alessandro Mauri Louis-Victor Delouvrier Nicolas Merigeau
CFO Investor Relations Media Relations
investors@ikonisys.com Ikonisys@newcap.eu Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 92 Tel.: +33 (0)1 44 71 94 98

Disclaimer
This press release contains forward-looking statements about the Company's prospects and development. These statements
are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative
of these terms or any other similar variants or expressions. This information is not historical data and should not be construed
as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates
considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic,
financial, competitive and regulatory environment. This information contains data relating to the Company's intentions,
estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of
the Company. The forward-looking information contained in this press release is made only as of the date of this press
release. The Company does not undertake to update any forward-looking information contained in this press release, except
as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and
therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking
information constitutes a guarantee of actual results.




2/2